Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome

被引：0
作者：
Kibum Kim
Daniel R. Touchette
Larisa H. Cavallari
Amer K. Ardati
Robert J. DiDomenico
机构：
[1] University of Utah,Department of Pharmacotherapy and Pharmacotherapy Outcomes Research Center
[2] University of Illinois at Chicago,Center for Pharmacoepidemiology and Pharmacoeconomic Research
[3] University of Illinois at Chicago,Department of Pharmacy Systems, Outcomes and Policy
[4] University of Florida,Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics
[5] University of Illinois at Chicago,Division of Cardiology
[6] University of Illinois at Chicago,Department of Pharmacy Practice
来源：
Cardiovascular Drugs and Therapy | 2019年 / 33卷
关键词：
Acute coronary syndrome; Personalized medicine; Ticagrelor; Clopidogrel; P2Y; inhibitors; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 546
页数：13
相关论文
共 681 条
  • [1] Benjamin EJ(2018)Heart disease and stroke statistics−2018 update: a report from the American Heart Association Circulation. 137 e67-e492
  • [2] Virani SS(2013)2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 61 e78-140
  • [3] Callaway CW(2014)2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines J Am Coll Cardiol 64 e139-e228
  • [4] Chamberlain AM(2016)2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines J Am Coll Cardiol 68 1082-1115
  • [5] Chang AR(2018)Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016 JAMA Intern Med 178 943-950
  • [6] Cheng S(2017)Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome J Manag Care Spec Pharm 23 57-63
  • [7] Chiuve SE(2013)Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update Clin Pharmacol Ther 94 317-323
  • [8] Cushman M(2012)Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel Am J Cardiol 110 502-508
  • [9] Delling FN(2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA. 304 1821-1830
  • [10] Deo R(2009)Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045-1057
12345678910